<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0172606</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-24347</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Gastrointestinal tumors</subject><subj-group><subject>Pancreatic cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Health care</subject><subj-group><subject>Health care providers</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Surgeons</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Professions</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Surgeons</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Health care</subject><subj-group><subject>Health care providers</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Physicians</subject><subj-group><subject>Surgeons</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Professions</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Physicians</subject><subj-group><subject>Surgeons</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Radiology and imaging</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Cancer chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Chemotherapy</subject><subj-group><subject>Cancer chemotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical medicine</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Cancer chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Cancer chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Plant science</subject><subj-group><subject>Plant anatomy</subject><subj-group><subject>Flower anatomy</subject><subj-group><subject>Calyx</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Renal cancer</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Clinically determined type of <sup>18</sup>F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer</article-title>
<alt-title alt-title-type="running-head">Clinical PET type for pancreatic cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chong</surname>
<given-names>Jae Uk</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hwang</surname>
<given-names>Ho Kyoung</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lee</surname>
<given-names>Jin Ho</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yun</surname>
<given-names>Mijin</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kang</surname>
<given-names>Chang Moo</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lee</surname>
<given-names>Woo Jung</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Pancreaticobiliary Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Seoul, Korea</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Surgery, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Chen</surname>
<given-names>Chin-Tu</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Chicago, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> CMK WJL.</p></list-item> <list-item><p><bold>Data curation:</bold> JUC HKH JHL MY CMK.</p></list-item> <list-item><p><bold>Formal analysis:</bold> JUC HKH JHL CMK.</p></list-item> <list-item><p><bold>Investigation:</bold> HKH JHL MY CMK.</p></list-item> <list-item><p><bold>Methodology:</bold> CMK WJL.</p></list-item> <list-item><p><bold>Project administration:</bold> CMK WJL.</p></list-item> <list-item><p><bold>Resources:</bold> MY CMK WJL.</p></list-item> <list-item><p><bold>Supervision:</bold> CMK WJL.</p></list-item> <list-item><p><bold>Validation:</bold> JUC HKH CMK WJL.</p></list-item> <list-item><p><bold>Visualization:</bold> JUC HKH JHL CMK.</p></list-item> <list-item><p><bold>Writing – original draft:</bold> JUC HKH CMK.</p></list-item> <list-item><p><bold>Writing – review &amp; editing:</bold> JUC HKH CMK WJL.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">cmkang@yuhs.ac</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>2</issue>
<elocation-id>e0172606</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Chong et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0172606"/>
<abstract>
<sec id="sec001">
<title>Purpose</title>
<p>To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar <sup>18</sup>FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower <sup>18</sup>FDG uptake than that of renal calyx was regarded as Non-K type.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (<italic>P</italic> = 0.030), adjusted CA 19–9 (<italic>P</italic> = 0.007), maximum standard uptake value (SUV<sub>max</sub>,<italic>P</italic>&lt;0.001), metabolic tumor volume (MTV<sub>2.5</sub>, <italic>P</italic>&lt;0.001), total lesion glycolysis (TLG, <italic>P</italic>&lt;0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, <italic>P</italic> = 0.013). It was also noted that aK-type showed inferior disease-free survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, <italic>P</italic> = 0.012).</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="6"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p><sup>18</sup>F-fluoro-2-deoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) scan is the functional imaging technology used to detect tumors with a high metabolic rate. It can also provide quantification of metabolic activity such as maximum standard uptake value (SUV<sub>max</sub>), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for estimating tumor biology and clinical translation [<xref ref-type="bibr" rid="pone.0172606.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0172606.ref002">2</xref>].</p>
<p>In general, overexpression of glucose transporters and hexokinases has been reported in many cancer cells[<xref ref-type="bibr" rid="pone.0172606.ref003">3</xref>]. <sup>18</sup>F-FDG is taken up by up-regulated surface glucose transporters and is phosphorylated by hexokinases. Glucose-6-phosphatase dephosphorylates glucose (FDG) to participate in the normal metabolic process. However, cancer cells have low expression of glucose-6-phosphatase compared to many normal tissues, and this can lead to an accumulation of <sup>18</sup>F-FDG-P in tumor cells[<xref ref-type="bibr" rid="pone.0172606.ref004">4</xref>–<xref ref-type="bibr" rid="pone.0172606.ref006">6</xref>]. The <sup>18</sup>F-FDG-PET scan is currently being used for cancer diagnosis[<xref ref-type="bibr" rid="pone.0172606.ref007">7</xref>], staging[<xref ref-type="bibr" rid="pone.0172606.ref008">8</xref>], identifying hidden metastasis, and assessment of treatment responses[<xref ref-type="bibr" rid="pone.0172606.ref009">9</xref>] in clinical oncology.</p>
<p>There have been several studies showing the oncologic significance of <sup>18</sup>F-FDG-PET scans in predicting prognosis in pancreatic cancer [<xref ref-type="bibr" rid="pone.0172606.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0172606.ref012">12</xref>]. Specifically, Dholakia et al[<xref ref-type="bibr" rid="pone.0172606.ref013">13</xref>] recently reported that MTV and TLG are significant prognostic factors of overall survival in patients with locally advanced pancreatic cancer. Epelbaum et al. [<xref ref-type="bibr" rid="pone.0172606.ref014">14</xref>] assessed the role of a quantitative dynamic PET model in pancreatic cancer and concluded that global <sup>18</sup>F-FDG influx was the most important parameter to predict overall survival. Yamamoto et al. [<xref ref-type="bibr" rid="pone.0172606.ref015">15</xref>] evaluated the clinical usefulness of <sup>18</sup>F-FDG-PET scans as a prognostic marker in resected pancreatic cancer and found that an SUV<sub>max</sub> greater than 6.0 was a significant predictor of early postoperative recurrence and poor survival in resected pancreatic cancer.</p>
<p>Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In addition, these parameters are somewhat subjective and prone to observer variability [<xref ref-type="bibr" rid="pone.0172606.ref016">16</xref>].</p>
<p>Interestingly, some studies have shown a potential relationship between image-based interpretation of tumors and oncologic outcome in treating malignant disease [<xref ref-type="bibr" rid="pone.0172606.ref017">17</xref>–<xref ref-type="bibr" rid="pone.0172606.ref021">21</xref>]. In this study, we analyzed the clinical feasibility of quick “qualitative” assessment of FDG-uptake in resectable pancreatic cancer by surgeons. We tried to correlate this clinical PET type with clinicopathological characteristic and oncologic outcome in resected pancreatic cancer. The goal of this study was to propose a qualitatively assessed clinical PET-type method that can be an alternative prognostic marker in resectable pancreatic cancer.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Patient selection and clinicopathologic characteristics</title>
<p>We retrospectively reviewed medical records of patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma. Only patients who underwent surgical resection with preoperative <sup>18</sup>F-FDG PET/CT as part of a staging work-up between January 2008 and October 2012 were included. Unresectable locally advanced pancreatic cancer and metastatic pancreatic cancer were excluded. In addition, those who received preoperative neoadjuvant treatment for borderline or locally advanced pancreatic cancer on preoperative imaging modalities were excluded due to potential impact of neoadjuvant treatment [<xref ref-type="bibr" rid="pone.0172606.ref022">22</xref>]. The study was reviewed and approved by the Institutional Review Board of Yonsei University College of Medicine.</p>
<p>The variables of gender, age, tumor location, operation type, tumor size, preoperative serum CA 19–9 (actual CA 19–9), adjusted CA 19–9 (calculated as actual CA 19–9 divided by initial serum bilirubin), grade (differentiation), pathologic tumor (pT) stage, presence of lymph node metastasis (pN), lymph node ratio (total number of metastatic lymph nodes divided by total number of retrieved lymph nodes), retrieved number of LNs, number of metastastic LNs, microscopic perineural invasion, lymphovascular invasion, recurrence, and time to recurrence were retrospectively reviewed. Maximum standard uptake value (SUV<sub>max</sub>), metabolic tumor volume (MTV<sub>2.5</sub>), and total lesion glycolysis (TLG) were measured by two nuclear medicine physicians as described previously [<xref ref-type="bibr" rid="pone.0172606.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0172606.ref023">23</xref>]. Each tumor was examined with a spherical-shaped volume of interest (VOI). SUV<sub>max</sub> of the VOI was calculated as (decay-corrected activity/tissue volume)/(injected dose/body weight). MTV<sub>2.5</sub> was defined as total tumor volume with an SUV of 2.5 or greater. TLG was calculated as (mean SUV) x (MTV<sub>2.5</sub>). In order to assess the possible influence of renal function on FDG uptake, estimated glomerular filtration rate (eGFR) and serum creatinine (Cr) levels were also reviewed.</p>
</sec>
<sec id="sec008">
<title>Determining clinical PET type</title>
<p>Perceived signal intensity of <sup>18</sup>FDG in the renal calyceal system was used as a reference to categorize clinical PET type. Pancreatic cancer with similar <sup>18</sup>FDG uptake to that of the renal calyx was determined as K-type (<xref ref-type="fig" rid="pone.0172606.g001">Fig 1a</xref>), and pancreatic cancer with relatively lower <sup>18</sup>FDG uptake than that of renal calyx was regarded as Non-K-type (<xref ref-type="fig" rid="pone.0172606.g001">Fig 1b</xref>). Three surgeons (Kang CM, Hwang HK, Lee JH) were asked to categorize the patients according to this defining system for clinical PET type. During the process of individual classification, the surgeons were not allowed to communicate regarding their interim results. However, the respectively determined clinical PET types were re-categorized as aK-type and aNon-K-type based on surgeon agreement. Agreement-based reclassification of clinical PET type follows the agreed upon classification of two surgeons. For example, if two surgeons determined a sample to be K-type and one surgeon concluded Non-K-type, the agreement-based reclassification of clinical PET type would be aK-type.</p>
<fig id="pone.0172606.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Determining clinical PET type based on perceived FDG-uptake intensity in the renal calyx.</title>
<p>(a) K-type, the perceived signal intensity of FDG-uptake in pancreatic head cancer (thick empty white arrow) is similar to that of the renal calyx(thin white arrow) (b) Non-K-type, the perceived signal intensity of FDG-uptake in pancreatic head cancer (thick empty white arrow) is lower than that of the renal calyx(thin white arrow).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec009">
<title>Statistical analysis</title>
<p>Continuous variables were described as mean ± standard deviation, and categorical variables were described as frequency (%). Student’s t-test was used for these determinations. To estimate inter-observer discrepancy, average agreement and Cohen’s Kappa values were analyzed, and results were defined as follows: poor &lt; 0.2, fair 0.21–0.4, moderate 0.41–0.6, substantial 0.61–0.8, and excellent 0.81–1[<xref ref-type="bibr" rid="pone.0172606.ref024">24</xref>]. Survival curves were estimated using the Kaplan-Meier method to calculate cumulative disease-free survival. Statistical analyses were performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). <italic>P</italic>-values&lt;0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Patient demographics and defining clinical PET type in resectable pancreatic cancer</title>
<p>A total of 53 patients were enrolled for this study (<xref ref-type="fig" rid="pone.0172606.g002">Fig 2</xref>). The clinicopathological characteristics are summarized in <xref ref-type="table" rid="pone.0172606.t001">Table 1</xref>. The mean disease-free survival was 20.8 months [95% CI: 15.6–26.1], and mean disease-specific survival was 30.5 months [95% CI: 24.3–36.7]. With regard to clinical PET type, 31 patients (58.5%) were found to have K-type, and 16 patients (31.2%) were Non-K-type. The other six patients (11.3%) had cancer whose type was unable to be agreed upon by all surgeons. In terms of renal function, all patients had normal serum Cr levels. However, 26 patients (49%) had eGFR below 90 mL/min/1.73m<sup>2</sup> with mild to moderate decrease [<xref ref-type="bibr" rid="pone.0172606.ref025">25</xref>]. There was no significant correlation between eGFR and SUV<sub>max</sub> in patient with normal serum creatinine levels (r = -0.115, <italic>P</italic> = 0.441).</p>
<table-wrap id="pone.0172606.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t001</object-id>
<label>Table 1</label> <caption><title>Clinicopathological characteristics of the patients.</title></caption>
<alternatives>
<graphic id="pone.0172606.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="left">Frequency, Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age (years)</td>
<td align="left">63.1 ± 9.2</td>
</tr>
<tr>
<td align="left">Gender (Female/Male)</td>
<td align="left">24/29</td>
</tr>
<tr>
<td align="left">Tumor Size, cm</td>
<td align="left">2.3 ± 0.7</td>
</tr>
<tr>
<td align="left">Location (Head/Body/Tail)</td>
<td align="left">38/12/3</td>
</tr>
<tr>
<td align="left">CA 19–9, U/mL</td>
<td align="left">509.6 ± 1675.9</td>
</tr>
<tr>
<td align="left">PD(PPPD)/DPS/TP</td>
<td align="left">6(32)/12/3</td>
</tr>
<tr>
<td align="left">Grade (W/M/P/U)</td>
<td align="left">8/39/6</td>
</tr>
<tr>
<td align="left">T stage (T1/T2/T3)</td>
<td align="left">2/2/49</td>
</tr>
<tr>
<td align="left">N stage (N0/N1)</td>
<td align="left">24/29</td>
</tr>
<tr>
<td align="left">Retrieved LNs</td>
<td align="left">18.3 ± 7.7</td>
</tr>
<tr>
<td align="left">Metastatic LNs</td>
<td align="left">1.3 ± 2.2</td>
</tr>
<tr>
<td align="left">LNR</td>
<td align="left">0.08 ± 0.11</td>
</tr>
<tr>
<td align="left">PNI (No/Yes)</td>
<td align="left">14/39</td>
</tr>
<tr>
<td align="left">LVI (No/Yes)</td>
<td align="left">34/19</td>
</tr>
<tr>
<td align="left">R0/R1/R2</td>
<td align="left">53/0/0</td>
</tr>
<tr>
<td align="left">SUV<sub>max</sub></td>
<td align="left">5.3 ± 2.8</td>
</tr>
<tr>
<td align="left">MTV<sub>2.5</sub></td>
<td align="left">3.9 ± 3.8</td>
</tr>
<tr>
<td align="left">TLG</td>
<td align="left">16.9 ± 20.9</td>
</tr>
<tr>
<td align="left">eGFR</td>
<td align="left">91.9 ± 18.9</td>
</tr>
<tr>
<td align="left">Serum Cr</td>
<td align="left">0.80 ± 0.20</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>PD, pancreaticoduodenectomy; PPPD, pylorus preserving pancreaticoduodenectomy; Grade (W/M/P/U), well-, moderate-, poor-, un-differentiated; LNs, lymph nodes; LNR, lymph node ratio; PNI, perineural invasion; LVI, lymphovascular invasion; SUV<sub>max</sub>, maximum standard uptake value; MTV<sub>2.5,</sub> metabolic tumor volume; TLG, total lesion glycolysis; eGFR, estimated glomerular filtration rate; Cr, creatinine</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="pone.0172606.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Patient eligibility.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec012">
<title>Correlations between clinicopathological characteristics and clinical PET type in resectable pancreatic cancer</title>
<p>There were no significant differences between K-type and Non-K-type pancreatic cancer in terms of clinicopathological characteristics such as tumor size, pT-stage, pN-stage, lymphovascular invasion, perineural invasion, and tumor differentiation (<italic>P</italic>&gt;0.05). However, SUV<sub>max</sub> (<italic>P</italic>&lt;0.001), MTV<sub>2.5</sub> (<italic>P</italic>&lt;0.001) and TLG (<italic>P</italic>&lt;0.001) were found to be statistically different between K-type and Non-K-type pancreatic cancer as determined by individual surgeons. Specifically, the actual CA 19–9 level appeared to be higher in K-type pancreatic cancer, but the difference was not significant (<italic>P</italic>&gt;0.05). However, the adjusted CA 19–9 was significantly different between two surgeons, S2 (448.6 ± 62.2 vs. 98.6 ± 153.9, <italic>P</italic> = 0.006) and S3 (434.8 ± 656.9 vs. 104.9 ± 156.3, <italic>P</italic> = 0.008, <xref ref-type="table" rid="pone.0172606.t002">Table 2</xref>).</p>
<table-wrap id="pone.0172606.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t002</object-id>
<label>Table 2</label> <caption><title>Clinicopathological differences according to individual surgeons’ clinical type of FDG-uptake.</title></caption>
<alternatives>
<graphic id="pone.0172606.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="3"/>
<th align="center" colspan="2">S1</th>
<th align="center" colspan="2">S2</th>
<th align="center" colspan="2">S3</th>
</tr>
<tr>
<th align="center">K</th>
<th align="center">Non-K</th>
<th align="center">K</th>
<th align="center">Non-K</th>
<th align="center">K</th>
<th align="center">Non-K</th>
</tr>
<tr>
<th align="center">(N = 34)</th>
<th align="center">(N = 19)</th>
<th align="center">(N = 33)</th>
<th align="center">(N = 20)</th>
<th align="center">(N = 34)</th>
<th align="center">(N = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Age, years</bold></td>
<td align="center">62.4 ± 9.9</td>
<td align="center">64.4 ± 7.6</td>
<td align="center">62.5 ± 9.9</td>
<td align="center">64.1 ± 7.9</td>
<td align="center">62.4 ± 9.9</td>
<td align="center">64.7 ± 7.8</td>
</tr>
<tr>
<td align="left"><bold>Gender (Female/Male)</bold></td>
<td align="center">15/19</td>
<td align="center">09/10</td>
<td align="center">14/19</td>
<td align="center">10/10</td>
<td align="center">14/20</td>
<td align="center">10/9</td>
</tr>
<tr>
<td align="left"><bold>Tumor Size, cm</bold></td>
<td align="center">2.5 ± 0.7</td>
<td align="center">2.3 ± 0.8</td>
<td align="center">2.5 ± 0.7</td>
<td align="center">2.2 ± 0.8</td>
<td align="center">2.5 ± 0.7</td>
<td align="center">2.2 ± 0.8</td>
</tr>
<tr>
<td align="left"><bold>Location (Head/Body/Tail)</bold></td>
<td align="center">22/9/3</td>
<td align="center">16/3/0</td>
<td align="center">23/8/2</td>
<td align="center">15/4/1</td>
<td align="center">23/8/3</td>
<td align="center">15/4/0</td>
</tr>
<tr>
<td align="left"><bold>Actual CA 19–9, U/mL</bold></td>
<td align="center">670.8 ± 2077.9</td>
<td align="center">221.1 ± 245.6</td>
<td align="center">703.7 ± 2104.2</td>
<td align="center">189.2 ± 237.2</td>
<td align="center">677.1 ± 2075.6</td>
<td align="center">209.9 ± 260.8</td>
</tr>
<tr>
<td align="left"><bold>Adjusted CA 19–9, U/mL</bold></td>
<td align="center">390.8 ± 625.1</td>
<td align="center">183.5 ± 379.4</td>
<td align="center">448.6 ± 62.2</td>
<td align="center">98.6 ± 153.9<xref ref-type="table-fn" rid="t002fn002"><sup>a</sup></xref></td>
<td align="center">434.8 ± 656.9</td>
<td align="center">104.9 ± 156.3<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left"><bold>Grade (W/M/P/U)</bold></td>
<td align="center">3/27/4</td>
<td align="center">5/12/2</td>
<td align="center">4/25/4</td>
<td align="center">4/14/2</td>
<td align="center">4/26/4</td>
<td align="center">4/13/2</td>
</tr>
<tr>
<td align="left"><bold>T stage (T1/T2/T3)</bold></td>
<td align="center">3/2/29</td>
<td align="center">2/2/15</td>
<td align="center">1/2/30</td>
<td align="center">1/0/19</td>
<td align="center">1/2/31</td>
<td align="center">1/0/18</td>
</tr>
<tr>
<td align="left"><bold>N stage (N0/N1)</bold></td>
<td align="center">15/19</td>
<td align="center">9/10</td>
<td align="center">14/19</td>
<td align="center">10/10</td>
<td align="center">14/10</td>
<td align="center">10/9</td>
</tr>
<tr>
<td align="left"><bold>Retrieved LNs</bold></td>
<td align="center">17.2 ± 6.9</td>
<td align="center">20.3 ± 8.6</td>
<td align="center">17.7 ± 7.9</td>
<td align="center">19.4 ± 8.6</td>
<td align="center">17.4 ± 7.1</td>
<td align="center">20.0 ± 8.6</td>
</tr>
<tr>
<td align="left"><bold>Metastatic LNs</bold></td>
<td align="center">1.3 ± 2.5</td>
<td align="center">1.4 ± 1.6</td>
<td align="center">1.3 ± 2.5</td>
<td align="center">1.4 ± 1.6</td>
<td align="center">1.3 ± 2.5</td>
<td align="center">1.4 ± 1.6</td>
</tr>
<tr>
<td align="left"><bold>LNR</bold></td>
<td align="center">0.08 ± 0.11</td>
<td align="center">0.09 ± 0.11</td>
<td align="center">0.07 ± 0.11</td>
<td align="center">0.08 ± 0.11</td>
<td align="center">0.07 ± 0.11</td>
<td align="center">0.08 ± 0.11</td>
</tr>
<tr>
<td align="left"><bold>PNI (No/Yes)</bold></td>
<td align="center">10/24</td>
<td align="center">4/15</td>
<td align="center">7/26</td>
<td align="center">7/13</td>
<td align="center">8/26</td>
<td align="center">6/13</td>
</tr>
<tr>
<td align="left"><bold>LVI (No/Yes)</bold></td>
<td align="center">22/12</td>
<td align="center">12/7</td>
<td align="center">22/11</td>
<td align="center">12/8</td>
<td align="center">22/12</td>
<td align="center">12/7</td>
</tr>
<tr>
<td align="left"><bold>R0/R1/R2</bold></td>
<td align="center">34/0/0</td>
<td align="center">19/0/0</td>
<td align="center">33/0/0</td>
<td align="center">20/0/0</td>
<td align="center">34/0/0</td>
<td align="center">19/0/0</td>
</tr>
<tr>
<td align="left"><bold>SUV</bold><sub><bold>max</bold></sub></td>
<td align="center">6.3 ± 2.9</td>
<td align="center">3.2 ± 0.6<xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></td>
<td align="center">6.3 ± 2.9</td>
<td align="center">3.2 ± 0.6<xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></td>
<td align="center">6.2 ± 2.9</td>
<td align="center">3.1 ± 0.6<xref ref-type="table-fn" rid="t002fn004"><sup>e</sup></xref></td>
</tr>
<tr>
<td align="left"><bold>MTV</bold><sub><bold>2.5</bold></sub></td>
<td align="center">5.5 ± 3.7</td>
<td align="center">0.8 ± 0.9<xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></td>
<td align="center">5.3 ± 3.8</td>
<td align="center">1.1 ± 1.6<xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></td>
<td align="center">5.4 ± 3.7</td>
<td align="center">0.7 ± 0.9<xref ref-type="table-fn" rid="t002fn004"><sup>e</sup></xref></td>
</tr>
<tr>
<td align="left"><bold>TLG</bold></td>
<td align="center">23.9 ± 22.5</td>
<td align="center">3.0 ± 3.7<xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></td>
<td align="center">23.7 ± 22.9</td>
<td align="center">4.4 ± 6.7<xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></td>
<td align="center">23.8 ± 22.5</td>
<td align="center">3.0 ± 4.1<xref ref-type="table-fn" rid="t002fn004"><sup>e</sup></xref></td>
</tr>
<tr>
<td align="left"><bold>Serum Cr</bold></td>
<td align="center">0.79 ± 0.19</td>
<td align="center">0.81 ± 0.22</td>
<td align="center">0.79 ± 0.19</td>
<td align="center">0.81 ± 0.21</td>
<td align="center">0.80 ± 0.19</td>
<td align="center">0.80 ± 0.21</td>
</tr>
<tr>
<td align="left"><bold>eGFR</bold></td>
<td align="center">91.4 ± 17.8</td>
<td align="center">92.7 ± 21.2</td>
<td align="center">91.5 ± 17.9</td>
<td align="center">92.5 ± 20.9</td>
<td align="center">92.2 ± 18.3</td>
<td align="center">91.2 ± 20.3</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>S1, surgeon1; S2, surgeon2; S3, surgeon3; Grade (W/M/P/U), well-, moderate-, poor-, un-differentiated; LNs, lymph nodes; LNR, lymph node ratio; PNI, perineural invasion; LVI, lymphovascular invasion; SUV<sub>max</sub>, maximum standard uptake value; MTV<sub>2.5,</sub> metabolic tumor volume; TLG, total lesion glycolysis; eGFR, estimated glomerular filtration rate; Cr, creatinine.</p></fn>
<fn id="t002fn002"><p><sup>a</sup> <italic>P</italic> = 0.006,</p></fn>
<fn id="t002fn003"><p><sup>b</sup> <italic>P</italic> = 0.008,</p></fn>
<fn id="t002fn004"><p><sup>c,d,e</sup> <italic>P</italic>&lt;0.001</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>Analysis of inter-surgeon agreement</title>
<p>Overall, the inter-surgeon agreement was greater than 91% with a pairwise Cohen’s kappa of 0.81 (<xref ref-type="table" rid="pone.0172606.t003">Table 3</xref>). After agreement-based reclassification, aK-type was noted in 34 patients (64.2%), and aNon-K-type pancreatic cancer was found in 19 patients (35.8%, <xref ref-type="table" rid="pone.0172606.t004">Table 4</xref>). There were significant statistical differences between agreement-based aNon-K-type and aK-type in adjusted CA 19–9 (102.8 ± 156.9 vs. 435.9 ± 656.3, <italic>P</italic> = 0.007), tumor size (2.0 ± 0.4 vs. 2.5 ± 0.7, <italic>P</italic> = 0.030), SUV<sub>max</sub> (3.1 ± 0.7 vs. 6.2 ± 2.8, <italic>P</italic>&lt;0.001), MTV<sub>2.5</sub> (1.0 ± 1.4 vs. 5.9 ± 4.6, <italic>P</italic>&lt;0.001), and TLG (3.2 ± 4.1 vs. 23.8 ± 22.6, <italic>P</italic>&lt;0.001).</p>
<table-wrap id="pone.0172606.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t003</object-id>
<label>Table 3</label> <caption><title>Inter-surgeon discrepancy.</title></caption>
<alternatives>
<graphic id="pone.0172606.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center">S1 and S2</th>
<th align="center">S2 and S3</th>
<th align="center">S3 and S1</th>
<th align="center">Average value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Pairwise percent agreement (%)</td>
<td align="char" char=".">88.679</td>
<td align="char" char=".">90.566</td>
<td align="char" char=".">94.34</td>
<td align="char" char=".">91.195</td>
</tr>
<tr>
<td align="left">Pairwise Cohen’s Kappa</td>
<td align="char" char=".">0.752</td>
<td align="char" char=".">0.797</td>
<td align="char" char=".">0.878</td>
<td align="char" char=".">0.81</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>S1, surgeon1; S2, surgeon2; S3, surgeon3</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0172606.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t004</object-id>
<label>Table 4</label> <caption><title>Agreement-based clinical PET type in six patients in whom not all three surgeons agreed on PET type.</title></caption>
<alternatives>
<graphic id="pone.0172606.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Patient Number</th>
<th align="center">S1</th>
<th align="center">S2</th>
<th align="center">S3</th>
<th align="center">Agreement-based decision<xref ref-type="table-fn" rid="t004fn002"><sup>1</sup></xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">1</td>
<td align="center">K-type</td>
<td align="center">Non K-type</td>
<td align="center">Non K-type</td>
<td align="center">aNon-K-type</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">Non K-type</td>
<td align="center">Non K-type</td>
<td align="center">K-type</td>
<td align="center">aNon-K-type</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">Non K-type</td>
<td align="center">K-type</td>
<td align="center">K-type</td>
<td align="center">aK-type</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">Non K-type</td>
<td align="center">K-type</td>
<td align="center">K-type</td>
<td align="center">aK-type</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">K-type</td>
<td align="center">Non K-type</td>
<td align="center">Non K-type</td>
<td align="center">aNon-K-type</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">K-type</td>
<td align="center">K-type</td>
<td align="center">Non K-type</td>
<td align="center">aK-type</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>S1, surgeon1; S2, surgeon2; S3, surgeon3</p></fn>
<fn id="t004fn002"><p><sup>1</sup>Agreement-based decision of clinical PET type follows the agreed upon classification of at least two surgeons</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Oncologic outcome according to clinical PET type in resectable pancreatic cancer</title>
<p>It was found that preoperatively determined clinical PET type could predict tumor recurrence after radical pancreatectomy. There was a significant difference in disease-free survival between individually determined K-type and Non-K-type resected pancreatic cancer (<italic>P</italic>&lt;0.05, <xref ref-type="table" rid="pone.0172606.t005">Table 5</xref>).</p>
<table-wrap id="pone.0172606.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t005</object-id>
<label>Table 5</label> <caption><title>Disease-free survival according to clinical PET type determined by individual surgeons.</title></caption>
<alternatives>
<graphic id="pone.0172606.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center"/>
<th align="center">K-type</th>
<th align="center">Non-K-type</th>
<th align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">S1</td>
<td align="center">17.6 months [95% CI:11.2–23.9]</td>
<td align="center">24.5 months [95% CI:17.7–31.4]</td>
<td align="char" char=".">0.035</td>
</tr>
<tr>
<td align="center">S2</td>
<td align="center">11.4 months [95% CI: 8.6–14.3]</td>
<td align="center">29.3 months [95% CI: 21.1–37.5]</td>
<td align="char" char=".">0.003</td>
</tr>
<tr>
<td align="center">S3</td>
<td align="center">11.9 months [95% CI: 9.1–14.7]</td>
<td align="center">29.6 months [95% CI: 20.9–38.2]</td>
<td align="char" char=".">0.007</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>S1, surgeon1; S2, surgeon2; S3, surgeon3; CI, confidence interval</p></fn>
</table-wrap-foot>
</table-wrap>
<p>When analyzing oncologic outcomes according to agreement of all three surgeons, K-type (N = 31, mean disease-free survival, 10.8 months [95% CI: 8.3–13.3]) showed significant early recurrence compared with Non-K-type pancreatic cancer (N = 16, mean disease-free survival, 24.1 months [95% CI: 24.4–54.8], <italic>P</italic> = 0.013). Disease-free survival of six patients with disagreed clinical type of <sup>18</sup>FDG uptake among the surgeons showed similar oncologic outcomes to Non-K-type patients (<italic>P</italic> = 0.237).</p>
<p>Finally, according to agreement-based reclassification, aK-type showed inferior mean disease-free survival compared to aNon-K-type pancreatic cancer (11.9 months [95% CI: 9.0–14.9] vs. 28.6 months [95% CI: 20.2–36.9], <italic>P</italic> = 0.012, <xref ref-type="fig" rid="pone.0172606.g003">Fig 3</xref>).</p>
<fig id="pone.0172606.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Oncologic outcomes according to agreement-based reclassification of clinical PET type.</title>
<p>aK-type, agreement-based K-type; aNon K-type, agreement-based Non K-type.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Oncologic impact of postoperative chemotherapy according to clinical PET type in resectable pancreatic cancer</title>
<p>Postoperative chemotherapy was offered to all patients after curative resection. However, 13 patients (25%) were not able to receive postoperative chemotherapy. Among these patients, 5 patients (38%) refused further treatment, 3 patients (24%) developed postoperative complications preventing postoperative chemotherapy in a timely manner, and remaining 5 patients (38%) did not recover well-enough for further treatment. There was no significant oncologic impact of postoperative chemotherapy on patients with aNon-K-type pancreatic cancer (mean 26.9 months [95% CI: 12.7–41.1] vs. 21.9 months [16.6–27.3], <italic>P</italic> = 0.780). However, postoperative chemotherapy played a very important role in patients with aK-type pancreatic cancer. In patients with aK-type pancreatic cancer, disease-free survival improved with postoperative chemotherapy (mean 5.6 months [95% CI: 3.6–7.6] vs. mean 12.8 months [95% CI: 9.7–16.0], <italic>P</italic> = 0.035), leading to comparable oncologic outcomes with aNon-K-type without postoperative chemotherapy (<italic>P</italic> = 0.262). Results of univariate and multivariate analysis of disease-free survival for aK-type have also revealed that postoperative chemotherapy is an independent prognostic factor in recurrence (HR 0.290, 95% CI: 0.086–0984, <italic>P</italic> = 0.047, <xref ref-type="table" rid="pone.0172606.t006">Table 6</xref>). However, postoperative chemotherapy still could not improve disease-free survival to the extent of aNon-K-type pancreatic cancer with postoperative chemotherapy (<italic>P</italic> = 0.043, <xref ref-type="fig" rid="pone.0172606.g004">Fig 4</xref>).</p>
<table-wrap id="pone.0172606.t006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.t006</object-id>
<label>Table 6</label> <caption><title>Univariate and multivariate analysis of disease-free survival for aK-type.</title></caption>
<alternatives>
<graphic id="pone.0172606.t006g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.t006" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Variables</th>
<th align="center" rowspan="2">N = 34 (%)</th>
<th align="left">Univariate analysis</th>
<th align="center" colspan="2">Multivariate analysis</th>
</tr>
<tr>
<th align="center">p-value</th>
<th align="center">p-value</th>
<th align="center">HR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age &gt; 65 years</td>
<td align="center">15 (44)</td>
<td align="char" char=".">0.309</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">Male gender</td>
<td align="center">20 (59)</td>
<td align="char" char=".">0.058</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">ASA score</td>
<td align="center"/>
<td align="char" char=".">0.591</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left"> 1</td>
<td align="center">11 (32)</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left"> 2</td>
<td align="center">20 (59)</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left"> 3</td>
<td align="center">3 (9)</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">Tumor size ≥ 2.5cm</td>
<td align="center">21 (62)</td>
<td align="char" char=".">0.802</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">AJCC 7<sup>th</sup> stage</td>
<td align="center"/>
<td align="char" char=".">0.960</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left"> I/IIA</td>
<td align="center">14 (41)</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left"> IIB</td>
<td align="center">20 (59)</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">Postoperative chemotherapy</td>
<td align="center">28 (82)</td>
<td align="char" char=".">0.035</td>
<td align="char" char=".">0.047</td>
<td align="center">0.290 (0.086-0.984)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<fig id="pone.0172606.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172606.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Oncologic role of postoperative chemotherapy according to clinical PET type in resectable pancreatic cancer.</title>
<p>aK-type, agreement-based K-type; aNon K-type, agreement-based Non K-type; CTx, postoperative chemotherapy.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.g004" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec016" sec-type="conclusions">
<title>Discussion</title>
<p><sup>18</sup>F-fluoro-2-deoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) is an emerging radiologic technique to detect functional (metabolic and biologic) properties of cancer [<xref ref-type="bibr" rid="pone.0172606.ref026">26</xref>,<xref ref-type="bibr" rid="pone.0172606.ref027">27</xref>]. <sup>18</sup>F-FDG-PET/CT is a potential preoperative image modality because tumor biology can be estimated using PET-based parameters even in preoperative staging situations.</p>
<p>In this study, we defined a qualitatively assessed clinical PET type and correlated it with oncologic outcome of resected pancreatic cancer. Pancreatic cancers with an available preoperative PET-scan could be divided into K-type and Non-K-type according to perceived signal intensity of <sup>18</sup>F-FDG uptake compared to that shown in the renal calyx. There are other potential candidates for a reference organ for determining the signal of <sup>18</sup>FDG uptake such as brain and myocardium. However, to compare the signal intensity of FDG uptake in a pancreatic tumor, one would need to frequently move the axial section-field to the chest level or even the brain area, which would be inconvenient during clinical assessment of metabolic properties in pancreatic cancer. On the contrary, the renal calyx can be easily visualized due to its proximity to the pancreas, allowing it to be easily used as a reference organ in determining clinical PET type in resected pancreatic cancer (<xref ref-type="fig" rid="pone.0172606.g001">Fig 1</xref>). Perceived intensity of FDG uptake in renal calyx may be different among patients. However, clinical PET typing is derived from comparison of perceived intensity of renal calyx and pancreatic cancer within the patient. This can be achieved easily in a single image with use of renal calyx as reference, which is in proximity to pancreas.</p>
<p>According to our results, the clinical PET type (K-type and Non-K-type) was found to successfully discriminate disease-free survival in resected pancreatic cancer (<italic>P</italic>&lt;0.05, <xref ref-type="fig" rid="pone.0172606.g003">Fig 3</xref> and <xref ref-type="table" rid="pone.0172606.t005">Table 5</xref>). Results of our finding concur with previously reported association between SUV<sub>max</sub> greater than 6.0 with early postoperative recurrence following resection of pancreatic cancer [<xref ref-type="bibr" rid="pone.0172606.ref015">15</xref>]. The present clinical PET type is based on surgeons’ perceptions of <sup>18</sup>FDG uptake in the tumor, with the renal calyx as the reference signal. Therefore, it is thought that clinical PET type can be very subjective and so might not be reliable. However, unlike our expectations, the agreement rate among three individual surgeons was estimated to be higher than 91.195% with a pairwise Cohen’s Kappa value of 0.81, suggesting excellent inter-observer variability. In previous reports, interobserver variation for SUV<sub>mean</sub> measurement has been noted up to 17% [<xref ref-type="bibr" rid="pone.0172606.ref028">28</xref>] and interobserver agreement for SUV<sub>max</sub> has been reported to be 91–93% [<xref ref-type="bibr" rid="pone.0172606.ref029">29</xref>]. This means that application of clinical PET type can be reliably used as an alternative detectable parameter to estimate tumor glucose metabolism and tumor biology in clinical setting.</p>
<p>Our data also showed a predictive value for tumor recurrence of clinical PET type, suggesting it as a potential clinical biomarker to predict recurrence before surgical intervention, especially when PET-based parameters are not documented in clinical practice. Biological mechanism behind our results may be explained by the role of SUV<sub>max</sub> in PET imaging. Kang et al. [<xref ref-type="bibr" rid="pone.0172606.ref030">30</xref>] reported that loss of SMAD4 is associated with poor oncologic outcome and this was correlated with SUV<sub>max</sub> to conclude that higher SUV<sub>max</sub> was associated with loss of SMAD4. Our results have shown that K-types have higher SUV<sub>max</sub> (<xref ref-type="table" rid="pone.0172606.t002">Table 2</xref>). This may explain poor disease-free survival of aK-type patients. Further research on role of PET imaging in prognosis of pancreatic cancer is needed.</p>
<p>There are several other advantages of the current qualitative method of determination of clinical PET type. First, the current system for determining clinical PET type is simple, easy, reproducible, and practical. Without specialized effort and equipment to measure PET-based parameters, surgeons or clinicians can estimate oncologic outcome during consultations with patients who have had a preoperative PET scan on spot.</p>
<p>Second, in spite of surgeons’ subjective determination, PET-based parameters of SUV<sub>max</sub>, MTV, and TLG were significantly different between K-type and Non-K-type pancreatic cancer (<xref ref-type="table" rid="pone.0172606.t004">Table 4</xref>). In addition, when correlating clinical PET type and preoperative serum CA 19–9, our data showed a higher level of preoperative actual CA 19–9, but the difference was not statistically significant. However, the adjusted CA 19–9 was found to be correlated with clinical PET type for surgeons S2 and S3, suggesting that clinical PET type can be a useful preoperative prognostic marker in resectable pancreatic cancer (<xref ref-type="table" rid="pone.0172606.t002">Table 2</xref>). These observations should be confirmed when analyzing data according to agreement-based clinical PET type.</p>
<p>Some studies have also suggested potential association between CA 19–9 and PET-based parameters. Shi et al[<xref ref-type="bibr" rid="pone.0172606.ref031">31</xref>] showed that MTV and TLG were most strongly correlated with serum CA 19–9 in patients with resected pancreatic cancer. Xu et al[<xref ref-type="bibr" rid="pone.0172606.ref012">12</xref>] also observed that MTV and TLG were significantly associated with baseline serum CA 19–9, and MTV and TLG showed strong consistency with baseline serum CA 19–9, leading to improved predictions of oncologic outcome in resectable pancreatic cancer. In fact, we have already studied the oncologic significance of adjusted CA 19–9 in predicting tumor recurrence in resected pancreatic cancer [<xref ref-type="bibr" rid="pone.0172606.ref032">32</xref>]. In the current data set, when setting the cut-off value of adjusted CA 19–9 to 80, we were able to predict disease-free survival in resected pancreatic cancer (<italic>P</italic> = 0.044, data not shown). Using a larger study volume, it will be necessary to validate this potential relationship between clinical PET type and serum CA 19–9 in the near future.</p>
<p>Finally, it was shown that preoperatively determined clinical PET type, especially, K-type pancreatic cancer, requires postoperative chemotherapy after radical pancreatectomy. According to our data, disease-free survival of aK-type pancreatic cancer is influenced by postoperative adjuvant chemotherapy (<xref ref-type="fig" rid="pone.0172606.g003">Fig 3</xref>), suggesting that aK-type resectable pancreatic cancer can benefit from postoperative chemotherapy. There are several studies evaluating the role of PET scans in monitoring the clinical outcomes of patients with locally advanced pancreatic cancer treated with neoadjuvant treatment[<xref ref-type="bibr" rid="pone.0172606.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0172606.ref033">33</xref>,<xref ref-type="bibr" rid="pone.0172606.ref034">34</xref>]. However, there are very few studies that have evaluated the potential role of preoperative PET scan in predicting the oncologic benefits of postoperative adjuvant chemotherapy in resectable pancreatic cancer. Our results suggest that preoperative PET scans can provide important data for decision for postoperative adjuvant chemotherapy after radical pancreatectomy in resectable pancreatic cancer.</p>
<p>Since the goal of this study was to assess feasibility of qualitatively determined clinical PET type by surgeons, patient population only included those under evaluation for operation. Therefore, the results of current study have limitation in application to unresectable patients. However, according to our clinical experiences of unresectable pancreatic cancer, most cases seem to belong to K-type, suggesting aggressive tumor biology. Further studies based on a larger population including unresectable cases are needed to confirm this observation.</p>
<p>This study is a retrospective study design harboring unavoidable selection bias because not all patients underwent preoperative PET and some patients with neoadjuvant treatment were excluded. In addition, PET parameters, especially SUV<sub>max</sub>, can be influenced by tumor size [<xref ref-type="bibr" rid="pone.0172606.ref035">35</xref>,<xref ref-type="bibr" rid="pone.0172606.ref036">36</xref>]. Therefore, it might be difficult to discriminate between K-type and Non-K-type in small pancreatic cancers, and our data supports this problem. This study showed that pancreatic cancer with disagreement in determination of clinical PET type was significantly smaller than the agreed cases (1.8 ± 0.3 cm vs. 2.5 ± 0.7 cm, <italic>P</italic> = 0.002). When analyzing patients with a radiologic tumor size greater than 2 cm, the average agreement rate increased to 93.3% with a mean pairwise Cohen’s Kappa value of 0.822. Finally, we may not be able to apply clinical PET type to all patients because there are also some clinical conditions that need to be considered, such as impaired renal function[<xref ref-type="bibr" rid="pone.0172606.ref037">37</xref>] and dehydration. <sup>18</sup>F-FDG is excreted through urine. Therefore, renal function plays an important role in <sup>18</sup>F-FDG metabolism. In patients with renal impairment, insulin-mediated glucose metabolism is also reduced because of insulin resistance [<xref ref-type="bibr" rid="pone.0172606.ref038">38</xref>]. This may influence FDG uptake in tissues. Accordingly, Torihara et al. [<xref ref-type="bibr" rid="pone.0172606.ref037">37</xref>] have reported that patients with renal dysfunction showed higher physiological FDG uptake in the soft tissue, spleen and blood pool. Despite the general assumption that impaired renal function would influence the distribution and metabolism of <sup>18</sup>F-FDG, recent report by Akers et al.[<xref ref-type="bibr" rid="pone.0172606.ref008">8</xref>] has shown that impaired renal function does not influence clearance of background activity of <sup>18</sup>F-FDG PET imaging. Minamimoto et al. [<xref ref-type="bibr" rid="pone.0172606.ref038">38</xref>] have also reported that suspected renal failure will not have a significant influence on assessment of PET imaging. In spite of these findings, FDG uptake in renal calyx is decreased in patients with impaired renal function because of reduced urine activity. Intense FDG uptake might not be seen even in the renal calyx due to the amount of urinary flow at the moment the image was taken. In those cases, the clinical PET type needs to be determined by anecdotal clinician’s memory of the usual intensity of FDG uptake in the renal calyx. Our study results did not include patients with impaired renal function. Limitations exist in determining clinical PET type for patients with abnormal renal functions, however our results have shown that with normal serum Cr levels, mild to moderate decrease in eGFR does not correlate with SUV<sub>max</sub>. Nevertheless, clinical information regarding renal function should be considered when applying clinical PET type.</p>
<p>In conclusion, the current results suggest the clinical feasibility of surgeons’ determined clinical PET type as alternative prognostic marker in resectable pancreatic cancer. True reliability and oncologic significance of clinical PET type need to be reassessed based on a prospective cohort of a large number of patients with resectable pancreatic cancer.</p>
</sec>
<sec id="sec017">
<title>Supporting information</title>
<supplementary-material id="pone.0172606.s001" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pone.0172606.s001" xlink:type="simple">
<label>S1 Data</label>
<caption>
<title>Available data.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0172606.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Castell</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Cook</surname> <given-names>GJ</given-names></name>. <article-title>Quantitative techniques in 18FDG PET scanning in oncology</article-title>. <source>Br J Cancer</source>. <year>2008</year>;<volume>98</volume>: <fpage>1597</fpage>–<lpage>1601</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.bjc.6604330" xlink:type="simple">10.1038/sj.bjc.6604330</ext-link></comment> <object-id pub-id-type="pmid">18475291</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moon</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Hyun</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>JY</given-names></name>. <article-title>Prognostic significance of volume-based PET parameters in cancer patients</article-title>. <source>Korean J Radiol</source>. <year>2013</year>;<volume>14</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3348/kjr.2013.14.1.1" xlink:type="simple">10.3348/kjr.2013.14.1.1</ext-link></comment> <object-id pub-id-type="pmid">23323025</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname> <given-names>TA</given-names></name>. <article-title>The rate-limiting step for tumor 18F fluoro-2-deoxy-D-glucose (FDG) incorporation</article-title>. <source>Nucl Med Biol</source>. <year>2001</year>;<volume>28</volume>: <fpage>1</fpage>–<lpage>4</lpage>. <object-id pub-id-type="pmid">11182558</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamada</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kubota</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kubota</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ido</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tamahashi</surname> <given-names>N</given-names></name>. <article-title>High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue</article-title>. <source>J Nucl Med</source>. <year>1995</year>;<volume>36</volume>: <fpage>1301</fpage>–<lpage>1306</lpage>. <object-id pub-id-type="pmid">7790960</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lodge</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Lucas</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Marsden</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Cronin</surname> <given-names>BF</given-names></name>, <name name-style="western"><surname>O'Doherty</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>MA</given-names></name>. <article-title>A PET study of 18FDG uptake in soft tissue masses</article-title>. <source>Eur J Nucl Med</source>. <year>1999</year>;<volume>26</volume>: <fpage>22</fpage>–<lpage>30</lpage>. <object-id pub-id-type="pmid">9933658</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakamoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Higashi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sakahara</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tamaki</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kogire</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Doi</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas</article-title>. <source>Cancer</source>. <year>2000</year>;<volume>89</volume>: <fpage>2547</fpage>–<lpage>2554</lpage>. <object-id pub-id-type="pmid">11135214</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawada</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Uehara</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hosoki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Takami</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shiroeda</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Arisawa</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors</article-title>. <source>Pancreas</source>. <year>2015</year>;<volume>44</volume>: <fpage>655</fpage>–<lpage>659</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MPA.0000000000000313" xlink:type="simple">10.1097/MPA.0000000000000313</ext-link></comment> <object-id pub-id-type="pmid">25815646</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>XY</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Jin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Guan</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Fu</surname> <given-names>DL</given-names></name>. <article-title>The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma</article-title>. <source>Hepatogastroenterology</source>. <year>2014</year>;<volume>61</volume>: <fpage>2102</fpage>–<lpage>2109</lpage>. <object-id pub-id-type="pmid">25722999</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinrich</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Schafer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Weber</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hany</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Bhure</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Pestalozzi</surname> <given-names>BC</given-names></name>, <etal>et al</etal>. <article-title>Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial</article-title>. <source>Ann Surg</source>. <year>2008</year>;<volume>248</volume>: <fpage>1014</fpage>–<lpage>1022</lpage>.</mixed-citation></ref>
<ref id="pone.0172606.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients with Pancreatic Cancer</article-title>. <source>J Nucl Med</source>. <year>2014</year>;<volume>55</volume>: <fpage>898</fpage>–<lpage>904</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.113.131847" xlink:type="simple">10.2967/jnumed.113.131847</ext-link></comment> <object-id pub-id-type="pmid">24711649</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>. <article-title>Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy</article-title>. <source>Yonsei Med J</source>. <year>2014</year>;<volume>55</volume>: <fpage>1498</fpage>–<lpage>1506</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3349/ymj.2014.55.6.1498" xlink:type="simple">10.3349/ymj.2014.55.6.1498</ext-link></comment> <object-id pub-id-type="pmid">25323885</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>HX</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>WQ</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>CT</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2014</year>;<volume>41</volume>: <fpage>1093</fpage>–<lpage>1102</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00259-014-2688-8" xlink:type="simple">10.1007/s00259-014-2688-8</ext-link></comment> <object-id pub-id-type="pmid">24522797</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dholakia</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Chaudhry</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Leal</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Raman</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Hacker-Prietz</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2014</year>;<volume>89</volume>: <fpage>539</fpage>–<lpage>546</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijrobp.2014.02.031" xlink:type="simple">10.1016/j.ijrobp.2014.02.031</ext-link></comment> <object-id pub-id-type="pmid">24751410</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Epelbaum</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Frenkel</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Haddad</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Sikorski</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Strauss</surname> <given-names>LG</given-names></name>, <name name-style="western"><surname>Israel</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT</article-title>. <source>J Nucl Med</source>. <year>2013</year>;<volume>54</volume>: <fpage>12</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.112.107466" xlink:type="simple">10.2967/jnumed.112.107466</ext-link></comment> <object-id pub-id-type="pmid">23166388</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamamoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sugiura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mizuno</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Okamura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Aramaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Endo</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma</article-title>. <source>Ann Surg Oncol</source>. <year>2015</year>;<volume>22</volume>: <fpage>677</fpage>–<lpage>684</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-014-4046-2" xlink:type="simple">10.1245/s10434-014-4046-2</ext-link></comment> <object-id pub-id-type="pmid">25190125</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Soret</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bacharach</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Buvat</surname> <given-names>I</given-names></name>. <article-title>Partial-volume effect in PET tumor imaging</article-title>. <source>J Nucl Med</source>. <year>2007</year>;<volume>48</volume>: <fpage>932</fpage>–<lpage>945</lpage>. <object-id pub-id-type="pmid">17504879</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Min</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>WK</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WJ</given-names></name>. <article-title>Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: Impact of intra-tumoral fat detected on chemical-shift images</article-title>. <source>Eur J Radiol</source>. <year>2015</year>;<volume>84</volume>: <fpage>1036</fpage>–<lpage>1043</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejrad.2015.03.002" xlink:type="simple">10.1016/j.ejrad.2015.03.002</ext-link></comment> <object-id pub-id-type="pmid">25818729</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fukukura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Takumi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Higashi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shinchi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kamimura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yoneyama</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Contrast-enhanced CT and diffusion-weighted MR imaging: performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma</article-title>. <source>Eur J Radiol</source>. <year>2014</year>;<volume>83</volume>: <fpage>612</fpage>–<lpage>619</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejrad.2013.12.016" xlink:type="simple">10.1016/j.ejrad.2013.12.016</ext-link></comment> <object-id pub-id-type="pmid">24418286</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Klotz</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Cha</surname> <given-names>SW</given-names></name>, <etal>et al</etal>. <article-title>Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy</article-title>. <source>Radiology</source>. <year>2009</year>;<volume>250</volume>: <fpage>110</fpage>–<lpage>117</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1148/radiol.2493080226" xlink:type="simple">10.1148/radiol.2493080226</ext-link></comment> <object-id pub-id-type="pmid">18984781</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>W</given-names></name>. <article-title>Associations between mammography and ultrasound imaging features and molecular characteristics of triple-negative breast cancer</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2014</year>;<volume>15</volume>: <fpage>3555</fpage>–<lpage>3559</lpage>. <object-id pub-id-type="pmid">24870756</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>YE</given-names></name>, <name name-style="western"><surname>Hwang</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>SH</given-names></name>, <etal>et al</etal>. <article-title>Clinical correlations with 18FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: still a surgical enigma?</article-title> <source>Pancreatology</source>. <year>2014</year>;<volume>14</volume>: <fpage>515</fpage>–<lpage>523</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pan.2014.08.003" xlink:type="simple">10.1016/j.pan.2014.08.003</ext-link></comment> <object-id pub-id-type="pmid">25256437</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Hwang</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WJ</given-names></name>. <article-title>Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer</article-title>. <source>Surg Oncol</source>. <year>2013</year>;<volume>22</volume>: <fpage>123</fpage>–<lpage>131</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.suronc.2013.02.007" xlink:type="simple">10.1016/j.suronc.2013.02.007</ext-link></comment> <object-id pub-id-type="pmid">23518243</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Jo</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Ryu</surname> <given-names>YH</given-names></name>, <etal>et al</etal>. <article-title>Prognostic significance of standardized uptake value on preoperative 18F-FDG PET/CT in patients with ampullary adenocarcinoma</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2015</year>;<volume>42</volume>: <fpage>841</fpage>–<lpage>847</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00259-014-2907-3" xlink:type="simple">10.1007/s00259-014-2907-3</ext-link></comment> <object-id pub-id-type="pmid">25216749</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Landis</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Koch</surname> <given-names>GG</given-names></name>. <article-title>The measurement of observer agreement for categorical data</article-title>. <source>Biometrics</source>. <year>1977</year>;<volume>33</volume>: <fpage>159</fpage>–<lpage>174</lpage>. <object-id pub-id-type="pmid">843571</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stevens</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Levin</surname> <given-names>A</given-names></name>. <article-title>Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline</article-title>. <source>Annals of internal medicine</source>. <year>2013</year>;<volume>158</volume>: <fpage>825</fpage>–<lpage>830</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00007" xlink:type="simple">10.7326/0003-4819-158-11-201306040-00007</ext-link></comment> <object-id pub-id-type="pmid">23732715</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dai</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Popa</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>MA</given-names></name>. <article-title>The role of 18F-FDG PET imaging in upper gastrointestinal malignancies</article-title>. <source>Curr Treat Options Oncol</source>. <year>2014</year>;<volume>15</volume>: <fpage>351</fpage>–<lpage>364</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11864-014-0301-9" xlink:type="simple">10.1007/s11864-014-0301-9</ext-link></comment> <object-id pub-id-type="pmid">25064175</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Donswijk</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Hess</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mulders</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>MG</given-names></name>. <article-title>Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies</article-title>. <source>PET Clin</source>. <year>2014</year>;<volume>9</volume>: <fpage>421</fpage>–<lpage>441</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cpet.2014.07.001" xlink:type="simple">10.1016/j.cpet.2014.07.001</ext-link></comment> <object-id pub-id-type="pmid">26050945</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adams</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Turkington</surname> <given-names>TG</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>TZ</given-names></name>. <article-title>A systematic review of the factors affecting accuracy of SUV measurements</article-title>. <source>American Journal of Roentgenology</source>. <year>2010</year>;<volume>195</volume>: <fpage>310</fpage>–<lpage>320</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2214/AJR.10.4923" xlink:type="simple">10.2214/AJR.10.4923</ext-link></comment> <object-id pub-id-type="pmid">20651185</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacene</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Leboulleux</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Baba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chatzifotiadis</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Goudarzi</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Teytelbaum</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy</article-title>. <source>Journal of Nuclear Medicine</source>. <year>2009</year>;<volume>50</volume>: <fpage>1760</fpage>–<lpage>1769</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.109.063321" xlink:type="simple">10.2967/jnumed.109.063321</ext-link></comment> <object-id pub-id-type="pmid">19837757</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Hwang</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>S-K</given-names></name>, <name name-style="western"><surname>Yun</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer</article-title>. <source>Medicine</source>. <year>2016</year>;<volume>95</volume>: <fpage>e3452</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MD.0000000000003452" xlink:type="simple">10.1097/MD.0000000000003452</ext-link></comment> <object-id pub-id-type="pmid">27124039</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ji</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer</article-title>. <source>Cancer Lett</source>. <year>2015</year>;<volume>360</volume>: <fpage>227</fpage>–<lpage>233</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2015.02.014" xlink:type="simple">10.1016/j.canlet.2015.02.014</ext-link></comment> <object-id pub-id-type="pmid">25687883</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WJ</given-names></name>, <etal>et al</etal>. <article-title>The use of adjusted preoperative CA 19–9 to predict the recurrence of resectable pancreatic cancer</article-title>. <source>J Surg Res</source>. <year>2007</year>;<volume>140</volume>: <fpage>31</fpage>–<lpage>35</lpage>. <object-id pub-id-type="pmid">17418869</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Heilbrun</surname> <given-names>LK</given-names></name>, <name name-style="western"><surname>Venkatramanamoorthy</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lawhorn-Crews</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Zalupski</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Shields</surname> <given-names>AF</given-names></name>. <article-title>Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer</article-title>. <source>Am J Clin Oncol</source>. <year>2010</year>;<volume>33</volume>: <fpage>257</fpage>–<lpage>261</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/COC.0b013e3181a76a0b" xlink:type="simple">10.1097/COC.0b013e3181a76a0b</ext-link></comment> <object-id pub-id-type="pmid">19806035</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Yun</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer</article-title>. <source>J Clin Gastroenterol</source>. <year>2006</year>;<volume>40</volume>: <fpage>923</fpage>–<lpage>929</lpage>. <object-id pub-id-type="pmid">17063113</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahn</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>WJ</given-names></name>. <article-title>Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer</article-title>. <source>Ann Nucl Med</source>. <year>2014</year>;<volume>28</volume>: <fpage>430</fpage>–<lpage>435</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12149-014-0833-x" xlink:type="simple">10.1007/s12149-014-0833-x</ext-link></comment> <object-id pub-id-type="pmid">24623151</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Obara</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Pu</surname> <given-names>Y</given-names></name>. <article-title>Prognostic value of metabolic tumor burden in lung cancer</article-title>. <source>Chin J Cancer Res</source>. <year>2013</year>;<volume>25</volume>: <fpage>615</fpage>–<lpage>622</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3978/j.issn.1000-9604.2013.11.10" xlink:type="simple">10.3978/j.issn.1000-9604.2013.11.10</ext-link></comment> <object-id pub-id-type="pmid">24385688</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Toriihara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kitazume</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nishida</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kubota</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nakadate</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tateishi</surname> <given-names>U</given-names></name>. <article-title>Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls</article-title>. <source>Am J Nucl Med Mol Imaging</source>. <year>2015</year>;<volume>5</volume>: <fpage>204</fpage>–<lpage>211</lpage>. <object-id pub-id-type="pmid">25973341</object-id></mixed-citation></ref>
<ref id="pone.0172606.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Minamimoto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Inoue</surname> <given-names>T</given-names></name>. <article-title>FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues</article-title>. <source>Annals of nuclear medicine</source>. <year>2007</year>;<volume>21</volume>: <fpage>217</fpage>–<lpage>222</lpage>. <object-id pub-id-type="pmid">17581720</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>